Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis

MS (multiple sclerosis) is a chronic autoimmune and neurodegenerative pathology of the CNS (central nervous system) affecting approx. 2.5 million people worldwide. Current and emerging DMDs (disease-modifying drugs) predominantly target the immune system. These therapeutic agents slow progression an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Yossan-Var, Waschek, James A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Neurochemistry 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189630/
https://www.ncbi.nlm.nih.gov/pubmed/21895607
http://dx.doi.org/10.1042/AN20110024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189630/
https://www.ncbi.nlm.nih.gov/pubmed/21895607
http://dx.doi.org/10.1042/AN20110024

Ejemplares similares